Who are Isomorphic Labs's decision-makers?
Isomorphic Labs is led by Demis Hassabis, Founder and CEO, with a leadership bench spanning product, science, operations, and commercialization.
- CEO
- Demis Hassabis
- Key exec
- Max Jaderberg
- Founded
- 2021
- Employees
- 300+ reported across London, Lausanne, and Cambridge
- HQ
- London, England
- Notable
- DeepMind co-founder and Nobel laureate leading Isomorphic and Google DeepMind.
- Demis HassabisFounder and CEOFounder · since 2021DeepMind co-founder and Nobel laureate leading Isomorphic and Google DeepMind.
- Max JaderbergPresident / AI leaderExecutiveFormer DeepMind researcher leading AI strategy.
- Miles CongreveChief Scientific OfficerExecutiveDrug-discovery scientist leading therapeutic science.
- Sergei YakneenChief Technology OfficerExecutiveTechnology leader for AI drug-design systems.
Who leads Isomorphic Labs?
Demis Hassabis serves as Founder and CEO; Max Jaderberg serves as President / AI leader; Miles Congreve serves as Chief Scientific Officer; Sergei Yakneen serves as Chief Technology Officer. The leadership pattern reflects the company's focus on ai drug discovery.
For outreach, leadership background matters because it shows whether decisions are likely to be product-led, science-led, clinical, industrial, or government-procurement heavy.
Who actually makes buying decisions at Isomorphic Labs?
Likely buying committees include the executive owner of Drug Design Engine, security and compliance leaders, finance/procurement, and the technical leaders responsible for integration.
A seller should avoid starting with a generic CEO pitch unless the offer is strategic. Most practical deals will need a functional champion who owns deployment pain and a finance or operations approver.
How is Isomorphic Labs organized as it scales?
Isomorphic Labs's public footprint suggests a scaling private company with cross-functional teams around product, engineering, customer deployment, and go-to-market or R&D. Exact reporting lines are not public.
The safest assumption is a matrixed buying process: technical validation first, operational proof second, and executive approval for larger commitments.
As of June 2026.Sources:Isomorphic Labs websiteIsomorphic Labs funding announcement
Isomorphic Labs — frequently asked questions
